The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksBodycote Regulatory News (BOY)

Share Price Information for Bodycote (BOY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 672.00
Bid: 673.00
Ask: 676.00
Change: -6.00 (-0.88%)
Spread: 3.00 (0.446%)
Open: 661.00
High: 680.00
Low: 661.00
Prev. Close: 678.00
BOY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

31 May 2023 07:00

RNS Number : 0860B
Bodycote PLC
31 May 2023
 

 

 

Wednesday 31 May 2023

 

Bodycote plc

Trading Update

 

Bodycote, the world's leading provider of heat treatment and specialist thermal processing services, issues a trading update covering the four-month period from 1 January to 30 April 2023 ("the period"), ahead of the Company's 70th Annual General Meeting, which will be held at 12.00pm today.

 

Trading Summary

We have had a good start to the year and trading in the first four months has been modestly ahead of our expectations. Guidance for the full year remains unchanged. Group revenue for the period was £281m (up 22.1% at actual rates and 16.6% higher at constant currency). Growth excluding energy surcharges was 9.5% at constant currency. Energy surcharges have steadily declined from their peak in Q4 2022 in line with the global trend in energy costs. Revenue in the period also benefitted from price increases which have enabled us to successfully mitigate the impact of other inflationary effects on our cost base.

 

Both the AGI and ADE businesses achieved good revenue growth in the period. AGI revenues were up 19.4% to £162m (at constant currency, up 14.4% and up 6.4% excluding surcharges), with ADE revenues 26.0% above last year to £119m (at constant currency, up 19.8% and up 13.8% excluding surcharges).

 

Specialist Technologies' revenue growth was 18.4% at constant currency, 15.0% excluding surcharges, with growth continuing to outperform our Classic Heat Treatment businesses, where revenues rose 15.9% at constant currency, 7.0% excluding surcharges. Specialist Technologies saw broad based growth across all of its key end markets.

 

Market Sectors

The following review of the Group's revenues by end market quotes all movements against the same period in 2022, at constant currency:

 

Aerospace & Defence revenues were 16.0% higher (9.4% excluding surcharges) led by good growth in Civil Aerospace (up 11.0% excluding surcharges) driven by OEM build rate increases and higher aftermarket demand. Aerospace supply chain issues are easing but remain an operational challenge for several of our customers.

 

Automotive revenues rose by 16.3% (8.8% excluding surcharges) against a relatively weak performance in this market in Q1 2022 when our customers had been impacted by supply chain issues and parts shortages. Growth in this market was led by strong progress in Emerging Markets. The outlook for the Automotive sector for the remainder of this year remains sensitive to the macro environment and consumer spending.

 

General Industrial (including Energy) revenues were up 17.1% (9.9% excluding surcharges). The slower growth we witnessed in certain General Industrial subsegments in Q4 has continued, but was more than offset by very strong growth in Oil & Gas during Q1 driven by specific project related activity, combined with good demand from Medical markets.

Emerging Markets revenues grew strongly, up 25.3% (18.9% excluding surcharges), driven by strong growth in Eastern Europe, where we continue to make good progress developing and expanding our market penetration. Revenues in China rose more modestly in the first four months reflecting slow automotive growth in the country in the period.

 

Financial position

Net debt (excluding lease liabilities) as at 30 April 2023 was £37.7m compared to £33.4m at 31 December 2022. This reflected bonus payments made in March together with our typical cash flow seasonality in the first quarter. Trade receivables rose, driven by the good revenue growth in the period.

 

Summary and Outlook

We have delivered good progress in the first four months, which underpins our confidence in delivering on the financial guidance for the full year that we provided with our 2022 results. While there are near term macroeconomic uncertainties, we expect underlying volume to continue to grow ahead of the background markets, and margins are expected to expand as surcharges moderate.

 

Beyond 2023, we expect robust growth, leading to further margin expansion. Civil Aerospace will benefit from higher OEM build rates and increasing airline flying hours, and our investments in Emerging Markets and Specialist Technologies will drive higher growth in these areas. The Board remains confident in the Group's prospects for continued profitable growth.

 

Trading Update Conference Call

The Company will be hosting a conference call for analysts and investors at 08.30am today (Wednesday 31 May 2023).

 

Participants' dial-in number:

United Kingdom Toll-Free: 0800 652 2435

United Kingdom Toll: +44 800 652 2435

International: +1 416 764 8652

 

Participants will be asked for names only; no PIN will be required

 

For further information, please contact:

 

Bodycote plc

Stephen Harris, Group Chief Executive

Ben Fidler, Chief Financial Officer

Tel: +44 1625 505 300

 

FTI Consulting

Richard Mountain

Susanne Yule

Tel: +44 203 727 1340

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRGDURSXDGXG
Date   Source Headline
22nd Apr 20247:00 amPRNTransaction in Own Shares
19th Apr 20247:00 amPRNTransaction in Own Shares
18th Apr 20247:00 amPRNTransaction in Own Shares
17th Apr 20247:00 amPRNTransaction in Own Shares
16th Apr 20247:00 amPRNTransaction in Own Shares
15th Apr 20247:00 amPRNTransaction in Own Shares
12th Apr 20247:00 amPRNTransaction in Own Shares
11th Apr 20247:00 amPRNTransaction in Own Shares
10th Apr 20247:00 amPRNTransaction in Own Shares
9th Apr 20247:00 amPRNTransaction in Own Shares
8th Apr 20247:00 amPRNTransaction in Own Shares
5th Apr 20247:00 amPRNTransaction in Own Shares
4th Apr 20249:50 amPRNAnnual Financial Report
4th Apr 20247:00 amPRNTransaction in Own Shares
3rd Apr 20247:00 amPRNTransaction in Own Shares
2nd Apr 20249:47 amPRNHolding(s) in Company
2nd Apr 20249:41 amPRNHolding(s) in Company
2nd Apr 20248:35 amPRNTransaction in Own Shares
28th Mar 20247:00 amPRNTransaction in Own Shares
27th Mar 20247:00 amPRNTransaction in Own Shares
26th Mar 20247:00 amPRNTransaction in Own Shares
25th Mar 20243:07 pmPRNDirector/PDMR Shareholding
25th Mar 20247:00 amPRNTransaction in Own Shares
22nd Mar 20247:00 amPRNTransaction in Own Shares
21st Mar 20242:55 pmPRNDirector/PDMR Shareholding
21st Mar 20242:29 pmPRNDirector/PDMR Shareholding
21st Mar 20247:00 amPRNTransaction in Own Shares
20th Mar 20247:00 amPRNTransaction in Own Shares
19th Mar 202411:24 amPRNDirector/PDMR Shareholding
19th Mar 20247:00 amPRNTransaction in Own Shares
18th Mar 20247:00 amPRNTransaction in Own Shares
15th Mar 20247:10 amRNSLaunch of £60 million Share Buyback Programme
15th Mar 20247:00 amRNSFull year results for year ended 31 December 2023
11th Mar 20247:00 amPRNBoard Change
1st Mar 20249:27 amPRNDirector Declaration
29th Feb 20244:30 pmPRNTotal Voting Rights
31st Jan 20244:30 pmPRNTotal Voting Rights
31st Jan 20243:57 pmPRNBodycote plc - Holding(s) in Company
22nd Jan 20247:00 amRNSAcquisition Update and Share Buyback Programme
8th Jan 20244:37 pmPRNHolding(s) in Company
29th Dec 202312:25 pmPRNTotal Voting Rights
8th Dec 20234:40 pmPRNDirector/PDMR Shareholding
30th Nov 20234:30 pmPRNTotal Voting Rights
22nd Nov 20237:00 amRNSTrading Update
10th Nov 202312:08 pmPRNDirector/PDMR Shareholding
9th Nov 20237:00 amRNSDirector Declaration
31st Oct 20234:30 pmPRNTotal Voting Rights
31st Oct 202310:07 amPRNDirector/PDMR Shareholding
18th Oct 20237:00 amRNSGroup Chief Executive Appointment
9th Oct 20237:00 amRNSSpecialist Tech Acquisitions & New HIP Facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.